Healthcare, Vol. 11, Pages 77: Prescription of Silexan Is Associated with Less Frequent General Practitioner Repeat Consultations Due to Disturbed Sleep Compared to Benzodiazepine Receptor Agonists: A Retrospective Database Analysis

Figure 1. Selection of study patients.

Healthcare 11 00077 g001

Figure 2. Kaplan–Meier curves for the time to the first repeat GP consultation for disturbed sleep in patients treated with Silexan versus Z-drugs.

Healthcare 11 00077 g002

Figure 3. Proportion of Silexan and Z-drug patients with a repeat diagnosis of sleep disorder within 15 days up to one year after the index date.

Healthcare 11 00077 g003

Table 1. Basic characteristics of the study sample after propensity score matching.

Table 1. Basic characteristics of the study sample after propensity score matching.

VariablePatients with Silexan PrescriptionPatients with Z-Drug Prescriptionp-ValueN520490,526 Age mean (SD)48.7 (19.2)61.5 (18.2)<0.00116–30 years [n (%)]1172 (22.5%)5948 (6.6%)<0.00131–40 years [n (%)]680 (13.1%)7255 (8.0%)<0.00141–50 years [n (%)]938 (18.0%)12,090 (13.4%)<0.00151–60 years [n (%)]982 (18.9%)16,669 (18.4%)0.40961–70 years [n (%)]594 (11.4%)14,668 (16.2%)<0.001>70 years [n (%)]838 (16.1%)33,896 (37.4%)<0.001Sex: female [n (%)]3456 (66.4%)53,982 (59.6%)<0.001Private health insurance [n (%)]622 (12.0%)9020 (10.0%)<0.001Depression1128 (21.7%)16,665 (18.4%)<0.001Anxiety disorder586 (11,3%)4945 (5.5%)<0.001Reaction to severe stress and adjustment disorder685 (13.2%)7226 (8.0%)<0.001Diabetes345 (6.6%)12,233 (13.5%)<0.001Back pain1216 (23.4%)20,396 (22.5%)0.161Osteoarthritis 392 (7.5%)9939 (11.0%)<0.001Chronic bronchitis/COPD210 (4.0%)6679 (7.4%)<0.001Cancer167 (3.2%)7864 (8.7%)<0.001

Table 2. Association between Silexan prescription and the probability of a repeated sleep disorder diagnosis within a period of 15–365 days after the index date (multivariable logistic regression).

Table 2. Association between Silexan prescription and the probability of a repeated sleep disorder diagnosis within a period of 15–365 days after the index date (multivariable logistic regression).

VariableOdds Ratio (95% CI) *p-ValueSilexan versus Z-Drugs0.56 (0.51–0.60)<0.001Male vs. female1.01 (0.98–1.04)0.659Age: 18–30 yearsReference Age: 31–40 years1.25 (1.15–1.36)<0.001Age: 41–50 years1.43 (1.32–1.54)<0.001Age: 51–60 years1.64 (1.52–1.76)<0.001Age: 61–70 years1.93 (1.79–2.08)<0.001Age: 70+ years2.49 (2.32–2.68)<0.001Private health insurance vs. statutory insurance1.23 (1.17–1.29)<0.001Depression1.35 (1.30–1.40)<0.001Anxiety disorder1.19 (1.12–1.26)<0.001Reaction to severe stress and adjustment disorder1.06 (1.01–1.12)0.030Diabetes1.33 (1.28–1.39)<0.001Back pain1.14 (1.10–1.18)<0.001Osteoarthritis1.24 (1.19–1.30)<0.001Chronic bronchitis/COPD1.37 (1.30–1.44)<0.001Cancer1.13 (1.08–1.19)<0.001

Table 3. Association between Silexan prescription and the probability of a repeat sleep disorder diagnosis within a period of 15–365 days after the index date, stratified by age group [Silexan versus Z-Drugs] (multivariable logistic regression).

Table 3. Association between Silexan prescription and the probability of a repeat sleep disorder diagnosis within a period of 15–365 days after the index date, stratified by age group [Silexan versus Z-Drugs] (multivariable logistic regression).

Age StratificationOdds Ratio (95% CI) *p-ValueAge: 16–30 years0.56 (0.46–0.69)<0.001Age: 31–40 years0.65 (0.52–0.82)<0.001Age: 41–50 years0.57 (0.47–0.69)<0.001Age: 51–60 years0.53 (0.44–0.63)<0.001Age: 61–70 years0.48 (0.38–0.59)<0.001Age: 70+ years0.58 (0.50–0.68)<0.001

留言 (0)

沒有登入
gif